#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Echinochrome A ( Ech A ) is a dark red pigment separated from sea urchin shell and spine and has a chemical structure of 6-ethyl-2,3,5,7,8-pentahydroxy-1,4-naphthoquinone .
2-1	16-28	Echinochrome	abstract[2]	new[2]	coref	2-8[4_2]
2-2	29-30	A	abstract[2]	new[2]	_	_
2-3	31-32	(	_	_	_	_
2-4	33-36	Ech	person	new	_	_
2-5	37-38	A	_	_	_	_
2-6	39-40	)	_	_	_	_
2-7	41-43	is	_	_	_	_
2-8	44-45	a	abstract[4]	giv[4]	_	_
2-9	46-50	dark	abstract[4]	giv[4]	_	_
2-10	51-54	red	abstract[4]	giv[4]	_	_
2-11	55-62	pigment	abstract[4]	giv[4]	_	_
2-12	63-72	separated	abstract[4]	giv[4]	_	_
2-13	73-77	from	abstract[4]	giv[4]	_	_
2-14	78-81	sea	abstract[4]|place|object[7]	giv[4]|new|new[7]	_	_
2-15	82-88	urchin	abstract[4]|animal|object[7]	giv[4]|new|new[7]	_	_
2-16	89-94	shell	abstract[4]|object[7]	giv[4]|new[7]	_	_
2-17	95-98	and	abstract[4]	giv[4]	_	_
2-18	99-104	spine	abstract[4]|object	giv[4]|new	_	_
2-19	105-108	and	_	_	_	_
2-20	109-112	has	_	_	_	_
2-21	113-114	a	abstract[9]	new[9]	_	_
2-22	115-123	chemical	abstract[9]	new[9]	_	_
2-23	124-133	structure	abstract[9]	new[9]	_	_
2-24	134-136	of	abstract[9]	new[9]	_	_
2-25	137-186	6-ethyl-2,3,5,7,8-pentahydroxy-1,4-naphthoquinone	abstract[9]|abstract	new[9]|new	_	_
2-26	187-188	.	_	_	_	_

#Text=As a main active component of a commercial therapeutic agent called ‘ histochrome ’ , Ech A has been used for the treatment of cardiovascular disorders and ophthalmopathic complications in Russia .
3-1	189-191	As	_	_	_	_
3-2	192-193	a	substance[11]	new[11]	_	_
3-3	194-198	main	substance[11]	new[11]	_	_
3-4	199-205	active	substance[11]	new[11]	_	_
3-5	206-215	component	substance[11]	new[11]	_	_
3-6	216-218	of	substance[11]	new[11]	_	_
3-7	219-220	a	substance[11]|substance[12]	new[11]|new[12]	_	_
3-8	221-231	commercial	substance[11]|substance[12]	new[11]|new[12]	_	_
3-9	232-243	therapeutic	substance[11]|substance[12]	new[11]|new[12]	_	_
3-10	244-249	agent	substance[11]|substance[12]	new[11]|new[12]	_	_
3-11	250-256	called	substance[11]|substance[12]	new[11]|new[12]	_	_
3-12	257-258	‘	substance[11]|substance[12]	new[11]|new[12]	_	_
3-13	259-270	histochrome	substance[11]|substance[12]|abstract	new[11]|new[12]|new	_	_
3-14	271-272	’	substance[11]|substance[12]	new[11]|new[12]	_	_
3-15	273-274	,	_	_	_	_
3-16	275-278	Ech	object	new	coref	4-7[21_0]
3-17	279-280	A	object	new	coref	6-11
3-18	281-284	has	_	_	_	_
3-19	285-289	been	_	_	_	_
3-20	290-294	used	_	_	_	_
3-21	295-298	for	_	_	_	_
3-22	299-302	the	abstract[16]	new[16]	coref	9-5[66_16]
3-23	303-312	treatment	abstract[16]	new[16]	_	_
3-24	313-315	of	abstract[16]	new[16]	_	_
3-25	316-330	cardiovascular	abstract[16]|abstract[17]	new[16]|new[17]	_	_
3-26	331-340	disorders	abstract[16]|abstract[17]	new[16]|new[17]	_	_
3-27	341-344	and	abstract[16]	new[16]	_	_
3-28	345-360	ophthalmopathic	abstract[16]|abstract[18]	new[16]|new[18]	_	_
3-29	361-374	complications	abstract[16]|abstract[18]	new[16]|new[18]	_	_
3-30	375-377	in	_	_	_	_
3-31	378-384	Russia	place	new	_	_
3-32	385-386	.	_	_	_	_

#Text=Among the several biological benefits of Ech A , anti-oxidant and anti-inflammatory capacity is proposed as a major underlying therapeutic mechanism .
4-1	387-392	Among	_	_	_	_
4-2	393-396	the	abstract[20]	new[20]	_	_
4-3	397-404	several	abstract[20]	new[20]	_	_
4-4	405-415	biological	abstract[20]	new[20]	_	_
4-5	416-424	benefits	abstract[20]	new[20]	_	_
4-6	425-427	of	abstract[20]	new[20]	_	_
4-7	428-431	Ech	abstract[20]|object[21]	new[20]|giv[21]	coref	5-3[0_21]
4-8	432-433	A	abstract[20]|object[21]	new[20]|giv[21]	_	_
4-9	434-435	,	_	_	_	_
4-10	436-448	anti-oxidant	abstract[22]	new[22]	_	_
4-11	449-452	and	abstract[22]	new[22]	_	_
4-12	453-470	anti-inflammatory	abstract[22]	new[22]	_	_
4-13	471-479	capacity	abstract[22]	new[22]	_	_
4-14	480-482	is	_	_	_	_
4-15	483-491	proposed	_	_	_	_
4-16	492-494	as	_	_	_	_
4-17	495-496	a	abstract[23]	new[23]	coref	16-3[136_23]
4-18	497-502	major	abstract[23]	new[23]	_	_
4-19	503-513	underlying	abstract[23]	new[23]	_	_
4-20	514-525	therapeutic	abstract[23]	new[23]	_	_
4-21	526-535	mechanism	abstract[23]	new[23]	_	_
4-22	536-537	.	_	_	_	_

#Text=Indeed , Ech A has been shown to attenuate the oxidative stress caused by reactive oxygen species ( ROS ) and cardiac toxic drugs , providing mitochondrial protection of cardiomyocyte .
5-1	538-544	Indeed	_	_	_	_
5-2	545-546	,	_	_	_	_
5-3	547-550	Ech	object	giv	coref	6-10
5-4	551-552	A	person	new	_	_
5-5	553-556	has	_	_	_	_
5-6	557-561	been	_	_	_	_
5-7	562-567	shown	_	_	_	_
5-8	568-570	to	_	_	_	_
5-9	571-580	attenuate	_	_	_	_
5-10	581-584	the	abstract[26]	new[26]	coref	6-26[0_26]
5-11	585-594	oxidative	abstract[26]	new[26]	_	_
5-12	595-601	stress	abstract[26]	new[26]	_	_
5-13	602-608	caused	abstract[26]	new[26]	_	_
5-14	609-611	by	abstract[26]	new[26]	_	_
5-15	612-620	reactive	abstract[26]|substance[27]|substance[28]	new[26]|new[27]|new[28]	appos	5-19[0_28]
5-16	621-627	oxygen	abstract[26]|substance[27]|substance[28]	new[26]|new[27]|new[28]	_	_
5-17	628-635	species	abstract[26]|substance[28]	new[26]|new[28]	_	_
5-18	636-637	(	_	_	_	_
5-19	638-641	ROS	substance	giv	coref	6-17
5-20	642-643	)	_	_	_	_
5-21	644-647	and	_	_	_	_
5-22	648-655	cardiac	substance[30]	new[30]	_	_
5-23	656-661	toxic	substance[30]	new[30]	_	_
5-24	662-667	drugs	substance[30]	new[30]	_	_
5-25	668-669	,	_	_	_	_
5-26	670-679	providing	_	_	_	_
5-27	680-693	mitochondrial	abstract[31]	new[31]	_	_
5-28	694-704	protection	abstract[31]	new[31]	_	_
5-29	705-707	of	abstract[31]	new[31]	_	_
5-30	708-721	cardiomyocyte	abstract[31]|person	new[31]|new	_	_
5-31	722-723	.	_	_	_	_

#Text=Park et al. have reported similar observations showing that Ech A reduced both cellular and mitochondrial ROS levels of patient-derived cardiac progenitors during the oxidative stress situation .
6-1	724-728	Park	person	new	_	_
6-2	729-731	et	_	_	_	_
6-3	732-735	al.	_	_	_	_
6-4	736-740	have	_	_	_	_
6-5	741-749	reported	_	_	_	_
6-6	750-757	similar	abstract[34]	new[34]	_	_
6-7	758-770	observations	abstract[34]	new[34]	_	_
6-8	771-778	showing	abstract[34]	new[34]	_	_
6-9	779-783	that	abstract[34]	new[34]	_	_
6-10	784-787	Ech	abstract[34]|object	new[34]|giv	coref	7-7
6-11	788-789	A	abstract[34]|object	new[34]|giv	_	_
6-12	790-797	reduced	abstract[34]	new[34]	_	_
6-13	798-802	both	abstract[34]|abstract[38]	new[34]|new[38]	coref	8-24[62_38]
6-14	803-811	cellular	abstract[34]|abstract[38]	new[34]|new[38]	_	_
6-15	812-815	and	abstract[34]|abstract[38]	new[34]|new[38]	_	_
6-16	816-829	mitochondrial	abstract[34]|abstract[38]	new[34]|new[38]	_	_
6-17	830-833	ROS	abstract[34]|substance|abstract[38]	new[34]|giv|new[38]	coref	9-10
6-18	834-840	levels	abstract[34]|abstract[38]	new[34]|new[38]	_	_
6-19	841-843	of	abstract[34]|abstract[38]	new[34]|new[38]	_	_
6-20	844-859	patient-derived	abstract[34]|abstract[38]|abstract[40]	new[34]|new[38]|new[40]	_	_
6-21	860-867	cardiac	abstract[34]|abstract[38]|person|abstract[40]	new[34]|new[38]|new|new[40]	_	_
6-22	868-879	progenitors	abstract[34]|abstract[38]|abstract[40]	new[34]|new[38]|new[40]	_	_
6-23	880-886	during	_	_	_	_
6-24	887-890	the	abstract[42]	new[42]	_	_
6-25	891-900	oxidative	abstract[42]	new[42]	_	_
6-26	901-907	stress	abstract|abstract[42]	giv|new[42]	_	_
6-27	908-917	situation	abstract[42]	new[42]	_	_
6-28	918-919	.	_	_	_	_

#Text=The anti-oxidative and anti-viral activity of Ech A has also been proved in vitro using a tick-borne encephalitis virus and herpes simplex virus type 1-infected cell models .
7-1	920-923	The	abstract[43]	new[43]	_	_
7-2	924-938	anti-oxidative	abstract[43]	new[43]	_	_
7-3	939-942	and	abstract[43]	new[43]	_	_
7-4	943-953	anti-viral	abstract[43]	new[43]	_	_
7-5	954-962	activity	abstract[43]	new[43]	_	_
7-6	963-965	of	abstract[43]	new[43]	_	_
7-7	966-969	Ech	abstract[43]|object|object[45]	new[43]|giv|giv[45]	coref|coref	7-7[45_0]|8-5[0_45]
7-8	970-971	A	abstract[43]|object[45]	new[43]|giv[45]	_	_
7-9	972-975	has	_	_	_	_
7-10	976-980	also	_	_	_	_
7-11	981-985	been	_	_	_	_
7-12	986-992	proved	_	_	_	_
7-13	993-995	in	_	_	_	_
7-14	996-1001	vitro	organization	new	coref	16-14
7-15	1002-1007	using	_	_	_	_
7-16	1008-1009	a	animal[48]	new[48]	coref	7-21[51_48]
7-17	1010-1020	tick-borne	animal[48]	new[48]	_	_
7-18	1021-1033	encephalitis	abstract|animal[48]	new|new[48]	_	_
7-19	1034-1039	virus	animal[48]	new[48]	_	_
7-20	1040-1043	and	_	_	_	_
7-21	1044-1050	herpes	animal|animal[51]|abstract[54]	new|giv[51]|new[54]	_	_
7-22	1051-1058	simplex	place|animal[51]|abstract[54]	new|giv[51]|new[54]	_	_
7-23	1059-1064	virus	animal[51]|abstract[54]	giv[51]|new[54]	_	_
7-24	1065-1069	type	abstract|abstract[54]	new|new[54]	_	_
7-25	1070-1080	1-infected	abstract[54]	new[54]	_	_
7-26	1081-1085	cell	object|abstract[54]	new|new[54]	_	_
7-27	1086-1092	models	abstract[54]	new[54]	_	_
7-28	1093-1094	.	_	_	_	_

#Text=The therapeutic potential of Ech A was also evaluated in an experimental gastric ulcer model where Ech A provided anti-ulcerogenic effects by increasing endogenous enzymatic and non-enzymatic antioxidant levels in vivo .
8-1	1095-1098	The	abstract[55]	new[55]	_	_
8-2	1099-1110	therapeutic	abstract[55]	new[55]	_	_
8-3	1111-1120	potential	abstract[55]	new[55]	_	_
8-4	1121-1123	of	abstract[55]	new[55]	_	_
8-5	1124-1127	Ech	abstract[55]|object	new[55]|giv	coref	8-17
8-6	1128-1129	A	abstract[55]	new[55]	_	_
8-7	1130-1133	was	_	_	_	_
8-8	1134-1138	also	_	_	_	_
8-9	1139-1148	evaluated	_	_	_	_
8-10	1149-1151	in	_	_	_	_
8-11	1152-1154	an	abstract[58]	new[58]	coref	9-22[75_58]
8-12	1155-1167	experimental	abstract[58]	new[58]	_	_
8-13	1168-1175	gastric	person[57]|abstract[58]	new[57]|new[58]	_	_
8-14	1176-1181	ulcer	person[57]|abstract[58]	new[57]|new[58]	_	_
8-15	1182-1187	model	abstract[58]	new[58]	_	_
8-16	1188-1193	where	abstract[58]	new[58]	_	_
8-17	1194-1197	Ech	abstract[58]|object	new[58]|giv	coref	9-5
8-18	1198-1199	A	abstract[58]	new[58]	_	_
8-19	1200-1208	provided	abstract[58]	new[58]	_	_
8-20	1209-1225	anti-ulcerogenic	abstract[58]|abstract[60]	new[58]|new[60]	coref	13-29[116_60]
8-21	1226-1233	effects	abstract[58]|abstract[60]	new[58]|new[60]	_	_
8-22	1234-1236	by	_	_	_	_
8-23	1237-1247	increasing	_	_	_	_
8-24	1248-1258	endogenous	abstract[62]	giv[62]	_	_
8-25	1259-1268	enzymatic	abstract[62]	giv[62]	_	_
8-26	1269-1272	and	abstract[62]	giv[62]	_	_
8-27	1273-1286	non-enzymatic	abstract[62]	giv[62]	_	_
8-28	1287-1298	antioxidant	person|abstract[62]	new|giv[62]	_	_
8-29	1299-1305	levels	abstract[62]	giv[62]	_	_
8-30	1306-1308	in	_	_	_	_
8-31	1309-1313	vivo	abstract	new	coref	17-3
8-32	1314-1315	.	_	_	_	_

#Text=In another study , Ech A treatment could reduce ROS production and pro-inflammatory tumor necrosis factor-α ( TNF-α ) secretion in a rat model of acute uveitis induced by lipopolysaccharide injection .
9-1	1316-1318	In	_	_	_	_
9-2	1319-1326	another	abstract[64]	new[64]	coref	15-2[123_64]
9-3	1327-1332	study	abstract[64]	new[64]	_	_
9-4	1333-1334	,	_	_	_	_
9-5	1335-1338	Ech	object|abstract[66]	giv|giv[66]	coref	10-6[79_0]
9-6	1339-1340	A	abstract[66]	giv[66]	_	_
9-7	1341-1350	treatment	abstract[66]	giv[66]	_	_
9-8	1351-1356	could	_	_	_	_
9-9	1357-1363	reduce	_	_	_	_
9-10	1364-1367	ROS	substance|abstract[68]	giv|new[68]	_	_
9-11	1368-1378	production	abstract[68]	new[68]	_	_
9-12	1379-1382	and	_	_	_	_
9-13	1383-1399	pro-inflammatory	abstract[73]	new[73]	_	_
9-14	1400-1405	tumor	object|abstract[71]|abstract[73]	new|new[71]|new[73]	appos	9-18[0_71]
9-15	1406-1414	necrosis	abstract|abstract[71]|abstract[73]	new|new[71]|new[73]	_	_
9-16	1415-1423	factor-α	abstract[71]|abstract[73]	new[71]|new[73]	_	_
9-17	1424-1425	(	abstract[73]	new[73]	_	_
9-18	1426-1431	TNF-α	abstract|abstract[73]	giv|new[73]	_	_
9-19	1432-1433	)	abstract[73]	new[73]	_	_
9-20	1434-1443	secretion	abstract[73]	new[73]	_	_
9-21	1444-1446	in	_	_	_	_
9-22	1447-1448	a	abstract[75]	giv[75]	coref	15-19[135_75]
9-23	1449-1452	rat	animal|abstract[75]	new|giv[75]	_	_
9-24	1453-1458	model	abstract[75]	giv[75]	_	_
9-25	1459-1461	of	abstract[75]	giv[75]	_	_
9-26	1462-1467	acute	abstract[75]|event[76]	giv[75]|new[76]	_	_
9-27	1468-1475	uveitis	abstract[75]|event[76]	giv[75]|new[76]	_	_
9-28	1476-1483	induced	abstract[75]|event[76]	giv[75]|new[76]	_	_
9-29	1484-1486	by	abstract[75]|event[76]	giv[75]|new[76]	_	_
9-30	1487-1505	lipopolysaccharide	abstract[75]|event[76]|event[77]	giv[75]|new[76]|new[77]	_	_
9-31	1506-1515	injection	abstract[75]|event[76]|event[77]	giv[75]|new[76]|new[77]	_	_
9-32	1516-1517	.	_	_	_	_

#Text=These previous findings imply that Ech A could exert a wide range of therapeutic impacts on other oxidative stress-related and inflammatory pathologic conditions ; however , the cell-type specific regulation of Ech A on the immune system , which consists of various innate and adaptive immune cells , has not been elucidated yet .
10-1	1518-1523	These	abstract[78]	new[78]	coref	17-1[153_78]
10-2	1524-1532	previous	abstract[78]	new[78]	_	_
10-3	1533-1541	findings	abstract[78]	new[78]	_	_
10-4	1542-1547	imply	_	_	_	_
10-5	1548-1552	that	_	_	_	_
10-6	1553-1556	Ech	object[79]	giv[79]	coref	10-32[0_79]
10-7	1557-1558	A	object[79]	giv[79]	_	_
10-8	1559-1564	could	_	_	_	_
10-9	1565-1570	exert	_	_	_	_
10-10	1571-1572	a	abstract[80]	new[80]	_	_
10-11	1573-1577	wide	abstract[80]	new[80]	_	_
10-12	1578-1583	range	abstract[80]	new[80]	_	_
10-13	1584-1586	of	abstract[80]	new[80]	_	_
10-14	1587-1598	therapeutic	abstract[80]|abstract[81]	new[80]|new[81]	_	_
10-15	1599-1606	impacts	abstract[80]|abstract[81]	new[80]|new[81]	_	_
10-16	1607-1609	on	abstract[80]|abstract[81]	new[80]|new[81]	_	_
10-17	1610-1615	other	abstract[80]|abstract[81]|abstract[83]	new[80]|new[81]|new[83]	_	_
10-18	1616-1625	oxidative	abstract[80]|abstract[81]|abstract[83]	new[80]|new[81]|new[83]	_	_
10-19	1626-1640	stress-related	abstract[80]|abstract[81]|abstract|abstract[83]	new[80]|new[81]|new|new[83]	_	_
10-20	1641-1644	and	abstract[80]|abstract[81]|abstract[83]	new[80]|new[81]|new[83]	_	_
10-21	1645-1657	inflammatory	abstract[80]|abstract[81]|abstract[83]	new[80]|new[81]|new[83]	_	_
10-22	1658-1668	pathologic	abstract[80]|abstract[81]|abstract[83]	new[80]|new[81]|new[83]	_	_
10-23	1669-1679	conditions	abstract[80]|abstract[81]|abstract[83]	new[80]|new[81]|new[83]	_	_
10-24	1680-1681	;	_	_	_	_
10-25	1682-1689	however	_	_	_	_
10-26	1690-1691	,	_	_	_	_
10-27	1692-1695	the	abstract[84]	new[84]	_	_
10-28	1696-1705	cell-type	abstract[84]	new[84]	_	_
10-29	1706-1714	specific	abstract[84]	new[84]	_	_
10-30	1715-1725	regulation	abstract[84]	new[84]	_	_
10-31	1726-1728	of	abstract[84]	new[84]	_	_
10-32	1729-1732	Ech	abstract[84]|object	new[84]|giv	coref	15-8[125_0]
10-33	1733-1734	A	abstract[84]	new[84]	_	_
10-34	1735-1737	on	abstract[84]	new[84]	_	_
10-35	1738-1741	the	abstract[84]|abstract[86]	new[84]|new[86]	_	_
10-36	1742-1748	immune	abstract[84]|abstract[86]	new[84]|new[86]	_	_
10-37	1749-1755	system	abstract[84]|abstract[86]	new[84]|new[86]	_	_
10-38	1756-1757	,	abstract[84]	new[84]	_	_
10-39	1758-1763	which	abstract[84]	new[84]	_	_
10-40	1764-1772	consists	abstract[84]	new[84]	_	_
10-41	1773-1775	of	abstract[84]	new[84]	_	_
10-42	1776-1783	various	abstract[84]|animal[87]	new[84]|new[87]	coref	16-20[143_87]
10-43	1784-1790	innate	abstract[84]|animal[87]	new[84]|new[87]	_	_
10-44	1791-1794	and	abstract[84]|animal[87]	new[84]|new[87]	_	_
10-45	1795-1803	adaptive	abstract[84]|animal[87]	new[84]|new[87]	_	_
10-46	1804-1810	immune	abstract[84]|animal[87]	new[84]|new[87]	_	_
10-47	1811-1816	cells	abstract[84]|animal[87]	new[84]|new[87]	_	_
10-48	1817-1818	,	_	_	_	_
10-49	1819-1822	has	_	_	_	_
10-50	1823-1826	not	_	_	_	_
10-51	1827-1831	been	_	_	_	_
10-52	1832-1842	elucidated	_	_	_	_
10-53	1843-1846	yet	_	_	_	_
10-54	1847-1848	.	_	_	_	_

#Text=Inflammatory bowel disease ( IBD ) is an intractable , chronic inflammatory disease of the digestive tract and Crohn 's disease ( CD ) and ulcerative colitis ( UC ) are the major types of IBD .
11-1	1849-1861	Inflammatory	abstract[89]	new[89]	appos	11-5[0_89]
11-2	1862-1867	bowel	object|abstract[89]	new|new[89]	_	_
11-3	1868-1875	disease	abstract[89]	new[89]	_	_
11-4	1876-1877	(	_	_	_	_
11-5	1878-1881	IBD	abstract	giv	coref	11-8[91_0]
11-6	1882-1883	)	_	_	_	_
11-7	1884-1886	is	_	_	_	_
11-8	1887-1889	an	abstract[91]|abstract[92]	giv[91]|giv[92]	coref|coref	11-8[92_91]|11-19[95_92]
11-9	1890-1901	intractable	abstract[91]|abstract[92]	giv[91]|giv[92]	_	_
11-10	1902-1903	,	abstract[91]|abstract[92]	giv[91]|giv[92]	_	_
11-11	1904-1911	chronic	abstract[91]|abstract[92]	giv[91]|giv[92]	_	_
11-12	1912-1924	inflammatory	abstract[91]|abstract[92]	giv[91]|giv[92]	_	_
11-13	1925-1932	disease	abstract[91]|abstract[92]	giv[91]|giv[92]	_	_
11-14	1933-1935	of	abstract[91]|abstract[92]	giv[91]|giv[92]	_	_
11-15	1936-1939	the	abstract[91]|abstract[92]|object[93]	giv[91]|giv[92]|new[93]	_	_
11-16	1940-1949	digestive	abstract[91]|abstract[92]|object[93]	giv[91]|giv[92]|new[93]	_	_
11-17	1950-1955	tract	abstract[91]|abstract[92]|object[93]	giv[91]|giv[92]|new[93]	_	_
11-18	1956-1959	and	abstract[92]	giv[92]	_	_
11-19	1960-1965	Crohn	abstract[92]|person[94]|abstract[95]	giv[92]|new[94]|giv[95]	appos	11-23[0_95]
11-20	1966-1968	's	abstract[92]|person[94]|abstract[95]	giv[92]|new[94]|giv[95]	_	_
11-21	1969-1976	disease	abstract[92]|abstract[95]	giv[92]|giv[95]	_	_
11-22	1977-1978	(	abstract[92]	giv[92]	_	_
11-23	1979-1981	CD	abstract[92]|abstract	giv[92]|giv	coref	11-36
11-24	1982-1983	)	abstract[92]	giv[92]	_	_
11-25	1984-1987	and	abstract[92]	giv[92]	_	_
11-26	1988-1998	ulcerative	abstract[92]|abstract|place[98]	giv[92]|new|new[98]	coref	11-32[100_98]
11-27	1999-2006	colitis	abstract[92]|place[98]	giv[92]|new[98]	_	_
11-28	2007-2008	(	abstract[92]	giv[92]	_	_
11-29	2009-2011	UC	abstract[92]|abstract	giv[92]|new	_	_
11-30	2012-2013	)	abstract[92]	giv[92]	_	_
11-31	2014-2017	are	abstract[92]	giv[92]	_	_
11-32	2018-2021	the	abstract[92]|place[100]	giv[92]|giv[100]	_	_
11-33	2022-2027	major	abstract[92]|place[100]	giv[92]|giv[100]	_	_
11-34	2028-2033	types	abstract[92]|place[100]	giv[92]|giv[100]	_	_
11-35	2034-2036	of	abstract[92]|place[100]	giv[92]|giv[100]	_	_
11-36	2037-2040	IBD	abstract[92]|place[100]|abstract	giv[92]|giv[100]|giv	coref	12-7
11-37	2041-2042	.	_	_	_	_

#Text=The etiology and pathogenic mechanisms of IBD remain largely unknown and both environmental factors and genetic factors combined with immunological dysfunction seem to drive IBD development .
12-1	2043-2046	The	abstract[102]	new[102]	_	_
12-2	2047-2055	etiology	abstract[102]	new[102]	_	_
12-3	2056-2059	and	_	_	_	_
12-4	2060-2070	pathogenic	abstract[103]	new[103]	_	_
12-5	2071-2081	mechanisms	abstract[103]	new[103]	_	_
12-6	2082-2084	of	abstract[103]	new[103]	_	_
12-7	2085-2088	IBD	abstract[103]|abstract	new[103]|giv	coref	12-25
12-8	2089-2095	remain	_	_	_	_
12-9	2096-2103	largely	_	_	_	_
12-10	2104-2111	unknown	_	_	_	_
12-11	2112-2115	and	_	_	_	_
12-12	2116-2120	both	abstract[105]	new[105]	_	_
12-13	2121-2134	environmental	abstract[105]	new[105]	_	_
12-14	2135-2142	factors	abstract[105]	new[105]	_	_
12-15	2143-2146	and	_	_	_	_
12-16	2147-2154	genetic	abstract[106]	new[106]	_	_
12-17	2155-2162	factors	abstract[106]	new[106]	_	_
12-18	2163-2171	combined	abstract[106]	new[106]	_	_
12-19	2172-2176	with	abstract[106]	new[106]	_	_
12-20	2177-2190	immunological	abstract[106]|abstract[107]	new[106]|new[107]	_	_
12-21	2191-2202	dysfunction	abstract[106]|abstract[107]	new[106]|new[107]	_	_
12-22	2203-2207	seem	_	_	_	_
12-23	2208-2210	to	_	_	_	_
12-24	2211-2216	drive	_	_	_	_
12-25	2217-2220	IBD	abstract|event[109]	giv|new[109]	coref	14-18
12-26	2221-2232	development	event[109]	new[109]	_	_
12-27	2233-2234	.	_	_	_	_

#Text=To attenuate the excessive immune response , advanced immunotherapy using immune-modulators such as inflammatory cytokine blockers has been used recently ; however , the presence of non-responder and uncontrolled side effects are the common challenging issues when using immunotherapy .
13-1	2235-2237	To	_	_	_	_
13-2	2238-2247	attenuate	_	_	_	_
13-3	2248-2251	the	abstract[110]	new[110]	_	_
13-4	2252-2261	excessive	abstract[110]	new[110]	_	_
13-5	2262-2268	immune	abstract[110]	new[110]	_	_
13-6	2269-2277	response	abstract[110]	new[110]	_	_
13-7	2278-2279	,	_	_	_	_
13-8	2280-2288	advanced	abstract[111]	new[111]	coref	13-39[0_111]
13-9	2289-2302	immunotherapy	abstract[111]	new[111]	_	_
13-10	2303-2308	using	abstract[111]	new[111]	_	_
13-11	2309-2326	immune-modulators	abstract[111]|abstract[112]	new[111]|new[112]	_	_
13-12	2327-2331	such	abstract[111]|abstract[112]	new[111]|new[112]	_	_
13-13	2332-2334	as	abstract[111]|abstract[112]	new[111]|new[112]	_	_
13-14	2335-2347	inflammatory	abstract[111]|abstract[112]|object[114]	new[111]|new[112]|new[114]	_	_
13-15	2348-2356	cytokine	abstract[111]|abstract[112]|substance|object[114]	new[111]|new[112]|new|new[114]	_	_
13-16	2357-2365	blockers	abstract[111]|abstract[112]|object[114]	new[111]|new[112]|new[114]	_	_
13-17	2366-2369	has	_	_	_	_
13-18	2370-2374	been	_	_	_	_
13-19	2375-2379	used	_	_	_	_
13-20	2380-2388	recently	_	_	_	_
13-21	2389-2390	;	_	_	_	_
13-22	2391-2398	however	_	_	_	_
13-23	2399-2400	,	_	_	_	_
13-24	2401-2404	the	abstract[115]	new[115]	coref	13-33[117_115]
13-25	2405-2413	presence	abstract[115]	new[115]	_	_
13-26	2414-2416	of	abstract[115]	new[115]	_	_
13-27	2417-2430	non-responder	abstract[115]	new[115]	_	_
13-28	2431-2434	and	abstract[115]	new[115]	_	_
13-29	2435-2447	uncontrolled	abstract[115]|abstract[116]	new[115]|giv[116]	_	_
13-30	2448-2452	side	abstract[115]|abstract[116]	new[115]|giv[116]	_	_
13-31	2453-2460	effects	abstract[115]|abstract[116]	new[115]|giv[116]	_	_
13-32	2461-2464	are	_	_	_	_
13-33	2465-2468	the	abstract[117]	giv[117]	_	_
13-34	2469-2475	common	abstract[117]	giv[117]	_	_
13-35	2476-2487	challenging	abstract[117]	giv[117]	_	_
13-36	2488-2494	issues	abstract[117]	giv[117]	_	_
13-37	2495-2499	when	abstract[117]	giv[117]	_	_
13-38	2500-2505	using	abstract[117]	giv[117]	_	_
13-39	2506-2519	immunotherapy	abstract[117]|abstract	giv[117]|giv	_	_
13-40	2520-2521	.	_	_	_	_

#Text=Therefore , there has been an unmet need to develop novel therapeutics for the effective management of IBD .
14-1	2522-2531	Therefore	_	_	_	_
14-2	2532-2533	,	_	_	_	_
14-3	2534-2539	there	_	_	_	_
14-4	2540-2543	has	_	_	_	_
14-5	2544-2548	been	_	_	_	_
14-6	2549-2551	an	abstract[119]	new[119]	_	_
14-7	2552-2557	unmet	abstract[119]	new[119]	_	_
14-8	2558-2562	need	abstract[119]	new[119]	_	_
14-9	2563-2565	to	abstract[119]	new[119]	_	_
14-10	2566-2573	develop	abstract[119]	new[119]	_	_
14-11	2574-2579	novel	abstract[119]|abstract[120]	new[119]|new[120]	_	_
14-12	2580-2592	therapeutics	abstract[119]|abstract[120]	new[119]|new[120]	_	_
14-13	2593-2596	for	abstract[119]|abstract[120]	new[119]|new[120]	_	_
14-14	2597-2600	the	abstract[119]|abstract[120]|organization[121]	new[119]|new[120]|new[121]	_	_
14-15	2601-2610	effective	abstract[119]|abstract[120]|organization[121]	new[119]|new[120]|new[121]	_	_
14-16	2611-2621	management	abstract[119]|abstract[120]|organization[121]	new[119]|new[120]|new[121]	_	_
14-17	2622-2624	of	abstract[119]|abstract[120]|organization[121]	new[119]|new[120]|new[121]	_	_
14-18	2625-2628	IBD	abstract[119]|abstract[120]|organization[121]|abstract	new[119]|new[120]|new[121]|giv	coref	15-16
14-19	2629-2630	.	_	_	_	_

#Text=In this study , we investigated whether Ech A could exhibit a protective role in IBD progression using a chemical colitogen dextran sodium sulfate ( DSS)-induced colitis mice model .
15-1	2631-2633	In	_	_	_	_
15-2	2634-2638	this	abstract[123]	giv[123]	_	_
15-3	2639-2644	study	abstract[123]	giv[123]	_	_
15-4	2645-2646	,	_	_	_	_
15-5	2647-2649	we	person	acc	ana	16-10
15-6	2650-2662	investigated	_	_	_	_
15-7	2663-2670	whether	_	_	_	_
15-8	2671-2674	Ech	object[125]	giv[125]	coref	16-7[137_125]
15-9	2675-2676	A	object[125]	giv[125]	_	_
15-10	2677-2682	could	_	_	_	_
15-11	2683-2690	exhibit	_	_	_	_
15-12	2691-2692	a	abstract[126]	new[126]	_	_
15-13	2693-2703	protective	abstract[126]	new[126]	_	_
15-14	2704-2708	role	abstract[126]	new[126]	_	_
15-15	2709-2711	in	abstract[126]	new[126]	_	_
15-16	2712-2715	IBD	abstract[126]|abstract|event[128]	new[126]|giv|new[128]	coref	17-31
15-17	2716-2727	progression	abstract[126]|event[128]	new[126]|new[128]	_	_
15-18	2728-2733	using	_	_	_	_
15-19	2734-2735	a	substance[132]|abstract[135]	new[132]|giv[135]	coref	17-26[159_135]
15-20	2736-2744	chemical	substance[132]|abstract[135]	new[132]|giv[135]	_	_
15-21	2745-2754	colitogen	substance|substance[132]|abstract[135]	new|new[132]|giv[135]	_	_
15-22	2755-2762	dextran	person|substance[132]|abstract[135]	new|new[132]|giv[135]	_	_
15-23	2763-2769	sodium	substance|substance[132]|abstract[135]	new|new[132]|giv[135]	_	_
15-24	2770-2777	sulfate	substance[132]|abstract[135]	new[132]|giv[135]	_	_
15-25	2778-2779	(	abstract[135]	giv[135]	_	_
15-26	2780-2792	DSS)-induced	abstract[135]	giv[135]	_	_
15-27	2793-2800	colitis	abstract|abstract[135]	new|giv[135]	coref	17-27
15-28	2801-2805	mice	animal|abstract[135]	new|giv[135]	_	_
15-29	2806-2811	model	abstract[135]	giv[135]	_	_
15-30	2812-2813	.	_	_	_	_

#Text=To explore the therapeutic mechanism of Ech A , we also performed in vitro proliferation and polarization experiments with two major innate and adaptive immune cells , macrophage and CD4+ helper T cells ( Th cells ) , respectively .
16-1	2814-2816	To	_	_	_	_
16-2	2817-2824	explore	_	_	_	_
16-3	2825-2828	the	abstract[136]	giv[136]	_	_
16-4	2829-2840	therapeutic	abstract[136]	giv[136]	_	_
16-5	2841-2850	mechanism	abstract[136]	giv[136]	_	_
16-6	2851-2853	of	abstract[136]	giv[136]	_	_
16-7	2854-2857	Ech	abstract[136]|object[137]	giv[136]|giv[137]	coref	17-7[154_137]
16-8	2858-2859	A	abstract[136]|object[137]	giv[136]|giv[137]	_	_
16-9	2860-2861	,	_	_	_	_
16-10	2862-2864	we	person	giv	ana	17-1
16-11	2865-2869	also	_	_	_	_
16-12	2870-2879	performed	_	_	_	_
16-13	2880-2882	in	_	_	_	_
16-14	2883-2888	vitro	organization	giv	coref	18-5
16-15	2889-2902	proliferation	abstract|event[142]	new|new[142]	_	_
16-16	2903-2906	and	event[142]	new[142]	_	_
16-17	2907-2919	polarization	abstract|event[142]	new|new[142]	_	_
16-18	2920-2931	experiments	event[142]	new[142]	_	_
16-19	2932-2936	with	event[142]	new[142]	_	_
16-20	2937-2940	two	event[142]|animal[143]	new[142]|giv[143]	appos	16-28[0_143]
16-21	2941-2946	major	event[142]|animal[143]	new[142]|giv[143]	_	_
16-22	2947-2953	innate	event[142]|animal[143]	new[142]|giv[143]	_	_
16-23	2954-2957	and	event[142]|animal[143]	new[142]|giv[143]	_	_
16-24	2958-2966	adaptive	event[142]|animal[143]	new[142]|giv[143]	_	_
16-25	2967-2973	immune	event[142]|animal[143]	new[142]|giv[143]	_	_
16-26	2974-2979	cells	event[142]|animal[143]	new[142]|giv[143]	_	_
16-27	2980-2981	,	_	_	_	_
16-28	2982-2992	macrophage	animal|animal[145]	giv|giv[145]	appos|appos	16-28[145_0]|16-30[149_145]
16-29	2993-2996	and	animal[145]	giv[145]	_	_
16-30	2997-3001	CD4+	animal[145]|abstract|animal[149]	giv[145]|new|giv[149]	appos	16-35[150_149]
16-31	3002-3008	helper	animal[145]|person|animal[149]	giv[145]|new|giv[149]	_	_
16-32	3009-3010	T	animal[145]|person|animal[149]	giv[145]|new|giv[149]	_	_
16-33	3011-3016	cells	animal[145]|animal[149]	giv[145]|giv[149]	_	_
16-34	3017-3018	(	_	_	_	_
16-35	3019-3021	Th	animal[150]	giv[150]	coref	18-23[166_150]
16-36	3022-3027	cells	animal[150]	giv[150]	_	_
16-37	3028-3029	)	_	_	_	_
16-38	3030-3031	,	_	_	_	_
16-39	3032-3044	respectively	_	_	_	_
16-40	3045-3046	.	_	_	_	_

#Text=Our in vivo findings suggest that Ech A could attenuate the clinical signs , as well as histological improvement , for the first time in a colitis model which represents IBD .
17-1	3047-3050	Our	person|abstract[153]	giv|giv[153]	_	_
17-2	3051-3053	in	abstract[153]	giv[153]	_	_
17-3	3054-3058	vivo	abstract|abstract[153]	giv|giv[153]	_	_
17-4	3059-3067	findings	abstract[153]	giv[153]	_	_
17-5	3068-3075	suggest	_	_	_	_
17-6	3076-3080	that	_	_	_	_
17-7	3081-3084	Ech	object[154]	giv[154]	coref	18-13[164_154]
17-8	3085-3086	A	object[154]	giv[154]	_	_
17-9	3087-3092	could	_	_	_	_
17-10	3093-3102	attenuate	_	_	_	_
17-11	3103-3106	the	abstract[155]	new[155]	_	_
17-12	3107-3115	clinical	abstract[155]	new[155]	_	_
17-13	3116-3121	signs	abstract[155]	new[155]	_	_
17-14	3122-3123	,	_	_	_	_
17-15	3124-3126	as	_	_	_	_
17-16	3127-3131	well	_	_	_	_
17-17	3132-3134	as	_	_	_	_
17-18	3135-3147	histological	abstract[156]	new[156]	_	_
17-19	3148-3159	improvement	abstract[156]	new[156]	_	_
17-20	3160-3161	,	_	_	_	_
17-21	3162-3165	for	_	_	_	_
17-22	3166-3169	the	time[157]	new[157]	_	_
17-23	3170-3175	first	time[157]	new[157]	_	_
17-24	3176-3180	time	time[157]	new[157]	_	_
17-25	3181-3183	in	time[157]	new[157]	_	_
17-26	3184-3185	a	time[157]|abstract[159]	new[157]|giv[159]	_	_
17-27	3186-3193	colitis	time[157]|abstract|abstract[159]	new[157]|giv|giv[159]	_	_
17-28	3194-3199	model	time[157]|abstract[159]	new[157]|giv[159]	_	_
17-29	3200-3205	which	time[157]|abstract[159]	new[157]|giv[159]	_	_
17-30	3206-3216	represents	time[157]|abstract[159]	new[157]|giv[159]	_	_
17-31	3217-3220	IBD	time[157]|abstract[159]|abstract	new[157]|giv[159]|giv	_	_
17-32	3221-3222	.	_	_	_	_

#Text=More importantly , in vitro results demonstrate that the anti-inflammatory function of Ech A is manifested by , in part , inducing immunomodulatory effector cells , such as M2 macrophages and Treg cells .
18-1	3223-3227	More	_	_	_	_
18-2	3228-3239	importantly	_	_	_	_
18-3	3240-3241	,	_	_	_	_
18-4	3242-3244	in	_	_	_	_
18-5	3245-3250	vitro	organization|abstract[162]	giv|new[162]	_	_
18-6	3251-3258	results	abstract[162]	new[162]	_	_
18-7	3259-3270	demonstrate	_	_	_	_
18-8	3271-3275	that	_	_	_	_
18-9	3276-3279	the	abstract[163]	new[163]	_	_
18-10	3280-3297	anti-inflammatory	abstract[163]	new[163]	_	_
18-11	3298-3306	function	abstract[163]	new[163]	_	_
18-12	3307-3309	of	abstract[163]	new[163]	_	_
18-13	3310-3313	Ech	abstract[163]|object[164]	new[163]|giv[164]	_	_
18-14	3314-3315	A	abstract[163]|object[164]	new[163]|giv[164]	_	_
18-15	3316-3318	is	_	_	_	_
18-16	3319-3329	manifested	_	_	_	_
18-17	3330-3332	by	_	_	_	_
18-18	3333-3334	,	_	_	_	_
18-19	3335-3337	in	_	_	_	_
18-20	3338-3342	part	_	_	_	_
18-21	3343-3344	,	_	_	_	_
18-22	3345-3353	inducing	_	_	_	_
18-23	3354-3370	immunomodulatory	animal[166]	giv[166]	coref	18-32[170_166]
18-24	3371-3379	effector	person|animal[166]	new|giv[166]	_	_
18-25	3380-3385	cells	animal[166]	giv[166]	_	_
18-26	3386-3387	,	animal[166]	giv[166]	_	_
18-27	3388-3392	such	animal[166]	giv[166]	_	_
18-28	3393-3395	as	animal[166]	giv[166]	_	_
18-29	3396-3398	M2	animal[166]|animal|animal[168]	giv[166]|new|new[168]	_	_
18-30	3399-3410	macrophages	animal[166]|animal[168]	giv[166]|new[168]	_	_
18-31	3411-3414	and	animal[166]	giv[166]	_	_
18-32	3415-3419	Treg	animal[166]|object|animal[170]	giv[166]|new|giv[170]	_	_
18-33	3420-3425	cells	animal[166]|animal[170]	giv[166]|giv[170]	_	_
18-34	3426-3427	.	_	_	_	_
